Insider Buying: Enochian Biosciences Inc (ENOB) Director Acquires 50,000 Shares of Stock

Share on StockTwits

Enochian Biosciences Inc (OTCMKTS:ENOB) Director Henrik Gronfeldt-Sorensen acquired 50,000 shares of the stock in a transaction dated Thursday, January 10th. The stock was bought at an average price of $2.00 per share, for a total transaction of $100,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

ENOB traded up $0.90 during trading on Friday, reaching $9.25. 202,653 shares of the company’s stock were exchanged, compared to its average volume of 81,111. Enochian Biosciences Inc has a fifty-two week low of $3.32 and a fifty-two week high of $9.50.

WARNING: “Insider Buying: Enochian Biosciences Inc (ENOB) Director Acquires 50,000 Shares of Stock” was reported by Macon Daily and is the property of of Macon Daily. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://macondaily.com/2019/01/11/insider-buying-enochian-biosciences-inc-enob-director-acquires-50000-shares-of-stock.html.

Enochian Biosciences Company Profile

Enochian Biosciences Inc, a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients.

Recommended Story: Stock Symbol

Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply